Psychiatr. pro Praxi, 2003; 2: 71-72

Bipolární afektivní porucha

doc. MUDr. Vladimír Pidrman Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V. Bipolární afektivní porucha. Psychiatr. praxi. 2003;4(2):71-72.

Bipolární afektivní porucha je rekurentní a ve své podstatě celoživotní onemocnění. Má fázický průběh, poměr mužů a žen je přibližně 1:1, celoživotní riziko je kolem 1 %. Od periodické depresivní poruchy ji z pohledu klinického odlišuje výskyt alespoň jedné fáze manické nebo hypomanické.

Download citation

References

  1. Basire S. Psychotropic drug directory 2002. Mark Alen Publishing, Ltd., Jesses Farm, 2001, 340 s.
  2. Bowden CL. New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology, 1998; 19, 3: 194-199. Go to original source... Go to PubMed...
  3. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investing Drugs, 2001; 10: 661-667. Go to original source... Go to PubMed...
  4. Clinical Practice Guideline. Depression. American Medical Directors Association, Columbia, 1996.
  5. Flint AJ, Rifat SL. Maintenance treatment for recurrent depression in late life: a four year outcome study. Am. J. Geriatr. Psychiatry, 2000; 8 (2): 112-116. Go to original source... Go to PubMed...
  6. Goldberg D. The management of anxious depression in primary care. Journal of Clinical Psychiatry 1999; 60 (Suppl 7): 39-42.
  7. Goodwin GM, Nolen WA, et al. Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy. European algorithm project. Int. Journ. of Psych. In Clinical Practice, 1977; 1 (suppl 1): S9-S12. Go to original source... Go to PubMed...
  8. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, Berlin, 2001: 2258 s. Go to original source...
  9. Herman E, Praško J, Hovorka J. Diagnostika a léčba bipolární poruchy. Maxdorf, Praha, 2003; 76 s.
  10. Hischfeld RMA, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry, 2000; 157: 1873-1875. Go to original source... Go to PubMed...
  11. Malhi GS, Bridges PK. Management of depression. Marin Dunitz, London, 1998: 130 s.
  12. Montgomery SA, den Boer JA. SSRIs depression and anxiety. John Wiley and Sons, Chichester, 1998; 194 s.
  13. National Disease and Therapeutic Index (NDTI). Plymouth Meeting, Pa: IMS Health: August 2001.
  14. Potter WZ. Bipolar depression: Specific treatments. J Clin Psychiatry, 1998; 59 (suppl 18): 30.
  15. Preskorn SH. Clinical pharmacology of SSRI. Professional Communication, Inc. Caddo, 1996: 226 s.
  16. Preskorn SH. Outpatient management of depression. Professional Communication, Inc., Caddo, 1999: 256 s.
  17. Raboch J, Zvolský P, et al. Psychiatrie. Praha, Galén a Univerzita Karlova, Karolinum, 2001: 622 p.
  18. Shiloh R, Nutt D, Weizman A. Atlas of psychotropic pharmacotherapy. Martin Dunitz, London, 2000: 235 s.
  19. Smolík P. Duševní a behaviorální poruchy. Průvodce klasifikací, nástin nozologie, diagnostika. Maxdorf, Praha, 1996: 504 s.
  20. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drug Aging, 2001; 18 (5): 355-368. Go to original source... Go to PubMed...
  21. Stahl MS. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge University Press, Cambridge, 2002; 602 s.
  22. Stahl MS. Essential psychopharmacology of depression and bipolar disorder. Cambridge University Press, Cambridge, 2000; 176 s.
  23. Stahl MS. Psychopharmacology of antidepressants. Martin Dunitz, London, 1997; 114 s.
  24. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am. J. Psychiatry, 1999; 156: 1264-1266. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.